Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Jackson

Showing results (161-170 of 170) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 170 results.
Nutrients|July 13, 2024
Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?Alex Pinto, Kirsten Ahring, Manuela Ferreira Almeida, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2024
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III TrialDaniel H Palmer, Richard Jackson, Christoph Springfeld, et al.
Lancet (London, England)|January 29, 2017
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trialJohn P Neoptolemos, Daniel H Palmer, Paula Ghaneh, et al.
Annals of Surgery|October 26, 2017
The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal AdenocarcinomaPaula Ghaneh, Jorg Kleeff, Christopher M Halloran, et al.
The Lancet. Gastroenterology & Hepatology|December 15, 2022
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trialPaula Ghaneh, Daniel Palmer, Silvia Cicconi, et al.
Journal of the National Cancer Institute|December 5, 2013
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trialWilliam Greenhalf, Paula Ghaneh, John P Neoptolemos, et al.
JAMA Surgery|September 5, 2019
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy TrialRobert P Jones, Eftychia-Eirini Psarelli, Richard Jackson, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|July 3, 2024
Diagnosis and management of selective fetal growth restriction in monochorionic twin pregnancies: A cross-sectional international surveySmriti Prasad, Asma Khalil, Jamie J Kirkham, et al.
Nature Genetics|February 23, 2021
The NCI Genomic Data CommonsAllison P Heath, Vincent Ferretti, Stuti Agrawal, et al.
Nature Genetics|May 19, 2021
Author Correction: The NCI Genomic Data CommonsAllison P Heath, Vincent Ferretti, Stuti Agrawal, et al.
Pageof 17

Showing results (161-170 of 170) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 170 results.
Nutrients|July 13, 2024
Blood Phenylalanine Levels in Patients with Phenylketonuria from Europe between 2012 and 2018: Is It a Changing Landscape?Alex Pinto, Kirsten Ahring, Manuela Ferreira Almeida, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2024
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III TrialDaniel H Palmer, Richard Jackson, Christoph Springfeld, et al.
Lancet (London, England)|January 29, 2017
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trialJohn P Neoptolemos, Daniel H Palmer, Paula Ghaneh, et al.
Annals of Surgery|October 26, 2017
The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal AdenocarcinomaPaula Ghaneh, Jorg Kleeff, Christopher M Halloran, et al.
The Lancet. Gastroenterology & Hepatology|December 15, 2022
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trialPaula Ghaneh, Daniel Palmer, Silvia Cicconi, et al.
Journal of the National Cancer Institute|December 5, 2013
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trialWilliam Greenhalf, Paula Ghaneh, John P Neoptolemos, et al.
JAMA Surgery|September 5, 2019
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy TrialRobert P Jones, Eftychia-Eirini Psarelli, Richard Jackson, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|July 3, 2024
Diagnosis and management of selective fetal growth restriction in monochorionic twin pregnancies: A cross-sectional international surveySmriti Prasad, Asma Khalil, Jamie J Kirkham, et al.
Nature Genetics|February 23, 2021
The NCI Genomic Data CommonsAllison P Heath, Vincent Ferretti, Stuti Agrawal, et al.
Nature Genetics|May 19, 2021
Author Correction: The NCI Genomic Data CommonsAllison P Heath, Vincent Ferretti, Stuti Agrawal, et al.
Pageof 17